410 Results
Sort By:
Published on April 11, 2024
Research led by Columbia University in New York has uncovered a genetic variant in the gene encoding fibronectin 1 (FN1) that protects against Alzheimer’s disease in carriers of the high risk APOE4 allele. It appears to do this by preventing excessive build-up of fibronectin in the blood brain barrier, something…
Published on April 4, 2024
Research led by Washington University in St. Louis carried out in animals shows that restoring the activity of microglial cells in the brain could be a new treatment strategy for Alzheimer’s disease. Approximately 5.8 million people in the United States have Alzheimer’s disease or related dementias. Treatments for the condition…
Published on March 21, 2024
New research published today by investigators from the Boston University School of Public Health (BUSPH) and the UTHealth Houston School of Public Health has identified 17 significant genetic variants in five genomic regions that are associated with Alzheimer’s disease (AD). The study, published in the journal Alzheimer’s & Dementia: The…
Published on March 7, 2024
Researchers from the University of Illinois Urbana-Champaign studying mouse models of Alzheimer’s disease (AD) have found the earliest biomarker of the disease to date. The biomarker, a neural-specific protein in the brain, exhibits increased activity that leads to seizures associated with the earliest stages of neurodegeneration. Reporting Wednesday in EMBO…
Published on March 1, 2024
Virtual reality headsets can reveal navigational issues in people at increased risk of Alzheimer’s disease before any declines in memory appear, research shows. The headsets flagged spatial navigation problems even when there were no concerns in cognitive tests, according to the findings in Alzheimer’s & Dementia: The Journal of the…
Published on December 20, 2023
Researchers from the Perelman School of Medicine at the University of Pennsylvania report that a protein “chaperone” molecule reversed Alzheimer’s disease (AD) signs and improved memory in a mouse model. Reporting in the journal Aging Biology, the investigators examined the effect a fatty-acid molecule called 4-phenylbutyrate (PBA) which has been…
Published on December 19, 2023
Digital biomarker company Altoida which is focused on using augmented reality and machine learning to identify neurological conditions, said that new research from the RADAR-AD consortium shows the promise of using augmented reality (AR)-based cognitive assessment for early identification and assessment of people with Alzheimer’s disease (AD). The findings, published…
Published on November 13, 2023
Renew Biotechnologies’ subsidiary Resonant recently published research in the journal Frontiers in Neurology of a new blood biomarker that promises earlier diagnosis of Alzheimer’s disease (AD). The approach, which centers on the use of cell-free DNA (cfDNA) analyzes differential methylation regions (DMRs) to identify biomarkers that can distinguish neuron-derived cfDNA…
Published on October 6, 2023
The Alzheimer’s Drug Discovery Foundation (ADDF) and the FINGERS Brain Health Institute (FBHI) have announced a new partnership that will focus on precision preventative measures physicians can take to slow, or potentially prevent, the onset of symptoms in Alzheimer’s disease based on each patient’s molecular profile. The partnership will center…
Published on August 11, 2023
Researchers at Arizona State University, publishing new findings in the journal Sciences Advances, have found that an Alzheimer’s disease (AD) genetic risk marker may have fertility benefits in women. The Apolipoprotein-ε4 (APOE-ε4) allele has been well studied and implicated in numerous studies for increased risk for a variety of diseases…
Published on July 14, 2023
Researchers at Washington University School of Medicine in St. Louis and Lund University in Lund, Sweden, have identified a form of the infamous Alzheimer’s biomarker tau that could be used to track progression of the disease. There are two main pathologies driving the progression of Alzheimer’s disease. During the onset…
Published on July 7, 2023
In a key step for Alzheimer’s disease (AD) treatment, the FDA has fully approved Biogen’s and Eisai’s Leqembi (lecanemab), the first drug shown to reduce the rate of disease progression and to slow cognitive and functional decline in adults. Several treatments are available that address symptoms of AD, but the…
Published on June 30, 2023
Researchers from the University of California San Francisco and pharma company Novo Nordisk have found that high levels of lean muscle mass could be protective against Alzheimer’s disease (AD). Obesity has been associated with a higher AD risk due to increase inflammation, insulin resistance, and higher levels of amyloid β,…
Published on June 19, 2023
Research led by Boston Medical Center has uncovered a link between biomarkers found in the vitreous humor of the eye and Alzheimer’s disease. As reported in the Journal of Alzheimer’s Disease, the research team also found a link with chronic traumatic encephalopathy (CTE) suggesting the biomarkers could “serve as a…
Published on June 16, 2023
Researchers at the Netherlands Institute for Neuroscience and the VIB-KU Leuven Center for Brain and Disease Research have discovered that a tiny molecule called microRNA-132 may play a significant role in the pathology of Alzheimer’s disease. Alzheimer’s disease is typically characterized by the buildup of protein aggregates called amyloid beta…